Q-omics provides the consensus-scored STMND1 profile across patient tissues and cancer cell-line models. STMND1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, STMND1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, STMND1 RNA expression shows 11,448 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight BRCA, KIRC, and SARC as cancer lineages where STMND1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STMND1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STMND1 survival associations across molecular data types. STMND1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STMND1 RNA expression–survival associations across cancer types. High STMND1 expression shows unfavorable associations in LGG, BLCA, THCA and KICH, but favorable associations in BRCA and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify BRCA as the clearest survival context for STMND1 RNA expression.
This table summarizes STMND1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STMND1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STMND1 shows lower tumor expression in KIRC, LUSC, LUAD and COAD and higher tumor expression in BRCA and LIHC. The KIRC box plot shows higher STMND1 RNA expression in normal versus tumor tissue (log2 FC = −0.031, t-test p < 0.001).
This table shows molecular features associated with STMND1 in patient tissues and cancer cell lines. In patient samples, STMND1 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, STMND1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
